Limited Benefit of Postexposure Prophylaxis With VSV-EBOV in Ebola Virus-Infected Rhesus Macaques

Trenton Bushmaker, Friederike Feldmann, Jamie Lovaglio, Greg Saturday, Amanda J. Griffin, Kyle L. O'Donnell, James E. Strong, Armand Sprecher, Gary Kobinger, Thomas W. Geisbert, Andrea Marzi, Heinz Feldmann

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Vesicular stomatitis virus-Ebola virus (VSV-EBOV) vaccine has been successfully used in ring vaccination approaches during EBOV disease outbreaks demonstrating its general benefit in short-term prophylactic vaccination, but actual proof of its benefit in true postexposure prophylaxis (PEP) for humans is missing. Animal studies have indicated PEP efficacy when VSV-EBOV was used within hours of lethal EBOV challenge. Here, we used a lower EBOV challenge dose and a combined intravenous and intramuscular VSV-EBOV administration to improve PEP efficacy in the rhesus macaque model. VSV-EBOV treatment 1 hour after EBOV challenge resulted in delayed disease progression but little benefit in outcome. Thus, we could not confirm previous results indicating questionable benefit of VSV-EBOV for EBOV PEP in a nonhuman primate model.

Original languageEnglish (US)
Pages (from-to)S721-S729
JournalJournal of Infectious Diseases
StatePublished - Nov 15 2023


  • Ebola virus
  • Ervebo
  • administration route
  • challenge dose
  • postexposure prophylaxis
  • rhesus macaque

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Limited Benefit of Postexposure Prophylaxis With VSV-EBOV in Ebola Virus-Infected Rhesus Macaques'. Together they form a unique fingerprint.

Cite this